Association of Vitamin D Receptor Gene Polymorphisms with Prostate Cancer Risk in the Pakistani Population |
Yousaf, Nageen
(Khyber Girls Medical Colleg)
Afzal, Sibtain (Prince Naif Center for Immunology Research, College of Medicine, King Saud University) Hayat, Tehreem (Department of Biotechnology, COMSATS Institute of Information Technology) Shah, Jasmin (Institute of Chemical Sciences, Peshawar University) Ahmad, Nafees (Department of Biomedical and Genetic Engineering) Abbasi, Rashda (Department of Biomedical and Genetic Engineering) Ramzan, Khushnooda (Department of Genetics, King Faisal Specialist Hospital and Research Centre) Jan, Rasul (University Peshawar) Khan, Imran (Institute of Basic Medical Sciences, Khyber Medical University) Ahmed, Jawad (Institute of Basic Medical Sciences, Khyber Medical University) Siraj, Sami (Institute of Basic Medical Sciences, Khyber Medical University) |
1 | Dianat SS, Margreiter M, Eckersberger E, et al (2009). Gene polymorphisms and prostate cancer: the evidence. BJU Int, 104, 1560-72. DOI |
2 | Feldman D, Skowronski RJ, Peehl DM (1995). Vitamin D and prostate cancer. Adv Exp Med Biol, 375, 53-63. |
3 | Giovannucci E (2009). Vitamin D and cancer incidence in the Harvard cohorts. Ann Epidemiol, 19, 84-8. DOI |
4 | Gross C, Krishnan AV, Malloy PJ, et al (1998). The vitamin D receptor gene start codon polymorphism: a functional analysis of FokI variants. J Bone Miner Res, 13, 1691-9. DOI ScienceOn |
5 | Guo Z, Wen J, Kan Q, et al (2013). Lack of association between vitamin D receptor gene FokI and BsmI polymorphisms and prostate cancer risk: an updated meta-analysis involving 21,756 subjects. Tumour Biol, 34, 3189-200. DOI |
6 | Harnden P, Naylor B, Shelley MD, et al (2008). The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression? A systematic review and meta-analysis. Cancer, 112, 971-81. DOI |
7 | Haussler MR, Jurutka PW, Hsieh JC, et al (1995). New understanding of the molecular mechanism of receptormediated genomic actions of the vitamin D hormone. Bone, 17, 33-8. DOI |
8 | Hendrickson WK, Flavin R, Kasperzyk JL, et al (2011). Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol, 29, 2378-85. DOI |
9 | Jamal S, Atique M, Khadim MT (2014). Changing pattern of malignancies: analysis of histopathology based tumour registry data and comparison of three decades at armed forces institute of pathology, Rawalpindi, Pakistan. J Pak Med Assoc, 64, 24-7. |
10 | Oh JJ, Byun SS, Lee SE, et al (2014). Genetic variations in VDR associated with prostate cancer risk and progression in a Korean population. Gene, 533, 86-93. DOI ScienceOn |
11 | Onen IH, Ekmekci A, Eroglu M, et al (2008). Association of genetic polymorphisms in vitamin D receptor gene and susceptibility to sporadic prostate cancer. Exp Biol Med (Maywood), 233, 1608-14. DOI |
12 | Peehl DM, Skowronski RJ, Leung GK, et al (1994). Antiproliferative effects of 1, 25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res, 54, 805-10. |
13 | Raimondi S, Johansson H, Maisonneuve P, et al (2009). Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis, 30, 1170-80. DOI ScienceOn |
14 | Rodriguez S, Gaunt TR, Day IN (2009). Hardy-weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol, 169, 505-14. |
15 | Scher HI, Heller G (2000). Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology, 55, 323-7. DOI |
16 | Sporn MB, Suh N (2002). Chemoprevention: an essential approach to controlling cancer. Nat Rev Cancer, 2, 537-43. DOI |
17 | Stangelberger A, Waldert M, Djavan B (2008). Prostate cancer in elderly men. Rev Urol, 10, 111-9. |
18 | Sun T, Lee GS, Werner L, et al (2010). Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. Cancer Epidemiol Biomarkers Prev, 19, 1871-8. DOI |
19 | Bai Y, Yu Y, Yu B, et al (2009). Association of vitamin D receptor polymorphisms with the risk of prostate cancer in the Han population of Southern China. BMC Med Genet, 10, 125. DOI |
20 | Arshad H, Ahmad Z (2013). Overview of benign and malignant prostatic disease in Pakistani patients: a clinical and histopathological perspective. Asian Pac J Cancer Prev, 14, 3005-10. 과학기술학회마을 DOI ScienceOn |
21 | Beer TM, Myrthue A (2004). Calcitriol in cancer treatment: from the lab to the clinic. Mol Cancer Ther, 3, 373-81. |
22 | Chen L, Davey Smith G, Evans DM, et al (2009). Genetic variants in the vitamin d receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. Cancer Epidemiol Biomarkers Prev, 18, 2874-81. DOI |
23 | Krishnan AV, Peehl DM, Feldman D (2003). Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem, 88, 363-71. DOI |
24 | Jensen SS, Madsen MW, Lukas J, et al (2001). Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phasecontrolling machinery. Mol Endocrinol, 15, 1370-80. |
25 | Koressaar T, Remm M (2007). Enhancements and modifications of primer design program Primer3. Bioinformatics, 23, 1289-91. DOI ScienceOn |
26 | Krishnan AV, Feldman D (2010). Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. Endocr Relat Cancer, 17, 19-38. |
27 | Lou YR, Qiao S, Talonpoika R, et al (2004). The role of Vitamin D3 metabolism in prostate cancer. J Steroid Biochem Mol Biol, 92, 317-25. DOI |
28 | Medeiros R, Morais A, Vasconcelos A, et al (2002). The role of vitamin D receptor gene polymorphisms in the susceptibility to prostate cancer of a southern European population. J Hum Genet, 47, 413-8. DOI |
29 | Miller GJ, Stapleton GE, Hedlund TE, et al (1995). Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res, 1, 997-1003. |
30 | Mishra DK, Bid HK, Srivastava DS, et al (2005). Association of vitamin D receptor gene polymorphism and risk of prostate cancer in India. Urol Int, 74, 315-8. DOI |
31 | Nelson WG, De Marzo AM, Isaacs WB (2003). Prostate cancer. N Engl J Med, 349, 366-81. DOI ScienceOn |
32 | Vanoirbeek E, Krishnan A, Eelen G, et al (2011). The anti-cancer and anti-inflammatory actions of 1, 25(OH)(2)D(3). Best Pract Res Clin Endocrinol Metab, 25, 593-604. DOI |
33 | Trump DL, Hershberger PA, Bernardi RJ, et al (2004). Antitumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol, 89-90, 519-26. DOI |
34 | Uitterlinden AG, Fang Y, Van Meurs JB, et al (2004). Genetics and biology of vitamin D receptor polymorphisms. Gene, 338, 143-56. DOI ScienceOn |
35 | Untergasser A, Cutcutache I, Koressaar T, et al (2012). Primer3- new capabilities and interfaces. Nucleic Acids Res, 40, 115. |
36 | Wang X, Wang S, Lin YW, et al (2012). Angiotensin-converting enzyme insertion/deletion polymorphism and the risk of prostate cancer in the Han population of China. Med Oncol, 29, 1964-71. DOI |
37 | Whitfield GK, Remus LS, Jurutka PW, et al (2001). Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol, 177, 145-59. DOI ScienceOn |
38 | Xu Y, He B, Pan Y, et al (2014). Systematic review and metaanalysis on vitamin D receptor polymorphisms and cancer risk. Tumour Biol, 35, 4153-69. DOI ScienceOn |
39 | Yin M, Wei S, Wei Q (2009). Vitamin D receptor genetic polymorphisms and prostate cancer risk: a meta-analysis of 36 published studies. Int J Clin Exp Med, 2, 159-75. |
40 | Zhang Q, Shan Y (2013). Genetic polymorphisms of vitamin D receptor and the risk of prostate cancer: a meta-analysis. J BUON, 18, 961-9. |